NAD+

NAD+, NMN and NR: Three Points on One Pathway

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

These are not alternatives to each other but successive stages of one pathway: NR converts to NMN, NMN converts to NAD+. Working backwards down the pathway gives smaller, more deliverable molecules, which is why the trial evidence sits with the precursors.

Key facts

NR
255.25 Da, two steps back
NMN
334.22 Da, one step back
NAD+
663.4 Da, the endpoint
Most trial data
NR
Highest-profile single result
NMN (Science 2021)
Hardest to deliver
NAD+

One pathway, three points

The framing as three competing products obscures the chemistry. Cells phosphorylate NR to make NMN, then adenylylate NMN to make NAD+. Choosing between them is choosing where to enter a sequence, not choosing between different mechanisms.

Why earlier is easier

Each step forward adds mass and charge. NR has no phosphate; NMN has one; NAD+ has two in a pyrophosphate bridge. Since charge is what blocks membrane crossing, the compound furthest back is the one most readily delivered, and the finished coenzyme is the one that cannot make the final step from outside a cell.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

Where the evidence sits

NR has the larger randomised trial footprint, including NADPARK in Cell Metabolism and Orr's placebo-controlled study in GeroScience. NMN has the single highest-profile result in Yoshino's 2021 Science paper on muscle insulin sensitivity, plus Yi's 2023 efficacy and safety work. NAD+ itself has almost no comparable randomised human literature.

The argument each side makes

NMN advocates note it is one step closer to the endpoint. NR advocates note it is smaller, uncharged at the relevant position, and has more trial data. Both arguments are reasonable and neither is decisive, because no trial has directly compared them on a meaningful endpoint.

What this means for a product labelled NAD+

It is the least-studied of the three in humans and the hardest to deliver into cells. That is the opposite of what the naming suggests: the finished molecule sounds like the most direct option and is in fact the least.

Quick reference

MWChargeRandomised human data
NR255.25 DaLowestMost
NMN334.22 DaIntermediateSome, incl. Science 2021
NAD+663.4 DaTwo phosphatesAlmost none

Frequently asked questions

Which is best?

No trial has compared them directly on a meaningful endpoint. NR has more randomised data; NMN has the highest-profile single result.

Why does NAD+ have the least data?

It is the hardest to deliver into cells, so researchers work with precursors instead.

Are they competing compounds?

No. They are successive stages of one conversion pathway. Choosing between them is choosing where to enter it.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.